深圳微芯生物科技股份有限公司 Shenzhen Chipscreen Biosciences Co. Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
The clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved 2024-11-01 19:04
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted 2024-10-17 21:38
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting 2024-10-15 22:08
Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration 2024-07-19 22:01
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma 2024-04-30 20:55
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis 2024-03-18 19:25
Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors 2024-01-16 17:00
Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis 2023-11-02 15:58
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan 2021-12-01 21:54
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan 2021-06-24 19:00
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA) 2021-04-16 18:24
Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA. 2021-01-11 11:33
Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation" 2021-01-05 17:49
Chipscreen and HISUN reach a strategic cooperation 2020-12-16 17:59
Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted 2020-03-24 19:25
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication 2019-11-29 20:22
Chipscreen and Novogene enter a strategic partnership for companion diagnostics development 2019-10-08 20:46
Chipscreen Biosciences's Oringinal New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted 2019-09-19 23:02
Chipscreen Biosciences Announces a Collaboration with Innovent to Evaluate Chidamide and the Combination of Sintilimab, Anti-VEGF Monoclonal Antibody IBI305 in Colorectal Cancer patients 2019-02-18 10:08
Chipscreen Biosciences Announces that a Pivotal Phase III Clinical Trial of Chidamide in Combination with Exemestane in Patients with Breast Cancer Reached Primary Endpoint 2018-05-29 18:00
1 2